RxDoctor Payments Data

Theodoros Katsivas

Infectious Disease · San Diego, CANPI 1679526164

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $25 of the $37 with a category attached, or 67.8%. Gilead accounts for 67.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for infectious disease clinicians in CA, where the typical reported total is $297.

$37in general payments, 2019–2025

Across 2 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$25
  • Paratek Pharmaceuticals, Inc.$12
$1,128,953in research payments, 2019–2025

Across 182 payments — averaging $6203.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bavarian Nordic A/s$611K
  • Seqirus USA Inc$251K
  • Cue Health Inc.$150K
  • Modernatx, Inc.$55K
  • AstraZeneca$33K
  • Merck$13K
  • plus $16K from 2 others

What the payments were for

  • Food & beverage$2568%
  • Education$1232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead1$25
Paratek Pharmaceuticals, Inc.1$12

How this compares

$37 in reported general payments places this provider in the 20th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Other infectious disease in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →